Kurser indlæses...
Prognose
| Køb |
1 |
| Behold |
0 |
| Sælg |
0 |
Nyheder Til nyhedsfeedet
SWK Holdings merges with Runway Growth Finance and is delisted by Nasdaq
SWK Holdings completed its merger with Runway Growth Finance and became a wholly owned subsidiary of Runway. Shareholders could elect to receive 1.7264 Runway common shares per SWK share or $20.59 in cash; Runway issued about 6.33 million shares and paid $173.54 million in cash. SWK filed for the delisting of its common shares and the suspension of SEC reporting obligations, all incumbent executives resigned, outstanding liabilities were fully repaid, and bond terms were adjusted to comply with the Investment Company Act. » Mere på de.investing.com
SWK Holdings: full repayment of loan to Elutia received after asset sale
SWK Holdings reports the full repayment of a loan to Elutia of USD 27.8 million, including principal, exit fees and accrued interest. The payment follows Elutia’s sale of its BioEnvelope business to Boston Scientific for USD 88.0 million. SWK says the receipt exceeds the loan’s net carrying value under GAAP and expects additional income from accelerated exit fees and the release of risk reserves. SWK also beat earnings expectations in Q2 2025 with earnings per share of USD 0.38. » Mere på de.investing.com
SWK Holdings beats Q2 earnings forecast, stock falls after results
SWK Holdings reported Q2 2025 EPS of $0.38, topping the $0.24 estimate. Cost cuts and asset sales produced GAAP pre-tax income of $4.6 million and net income of $3.5 million. The company paid $49 million in dividends, sharply reduced operating expenses and expects transitions in Q3 related to the sale of "Mod three." Despite the positive results, the stock fell in after-hours and pre-market trading, which investors say reflects concerns about the strategic realignment and regulatory risks. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | december 2025 | YoY |
|---|---|---|
| Omsætning | 7,41 mio. | - |
| Bruttofortjeneste | 0 | - |
| Nettoresultat | -16,52 mio. | - |
| EBITDA | 35,8 t | - |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 171,01 mio. € |
Antal aktier | 12,1 mio. |
Højeste/laveste i 52 uger | 15,92 € - 11,15 € |
| Udbytte | Nej |
Beta | 0,30 |
P/E (PE Ratio) | -43,47 |
PEG (PEG Ratio) | 0,28 |
K/I (PB Ratio) | 1,30 |
P/S (PS Ratio) | 6,52 |
Virksomhedsprofil
SWK Holdings Corporation er et specialiseret finansieringsselskab, der fokuserer på sundhedssektoren. Virksomheden opererer i to segmenter, Finance Receivables og Pharmaceutical Development. Selskabet tilbyder skræddersyede finansieringsløsninger til en række life science-virksomheder, herunder virksomheder inden for bioteknologi, medicinsk udstyr, medicinsk diagnostik og relaterede værktøjer, dyresundhed og lægemiddelindustrien samt institutioner og opfindere. Selskabet tilbyder også ikke-diskretionær investeringsrådgivning til institutionelle kunder i separat forvaltede konti for at investere i life science-finansiering. Derudover er selskabet aktivt inden for udvikling, formulering og fremstilling af lægemidler samt licensforretning gennem Peptelligence-platformen. Virksomhedens produktpipeline omfatter Ovarest, en oral leuprolidtablet til behandling af endokrine sygdomme. Selskabet var tidligere kendt som Kana Software, Inc. og skiftede navn til SWK Holdings Corporation i december 2009. SWK Holdings Corporation blev grundlagt i 1996 og har hovedkontor i Dallas, Texas.
| Navn | SWK HOLDINGS DL-,001 |
| CEO | Jody. D Staggs |
| Hjemsted | Dallas,
tx USA |
| Websted | |
| Sektor | Industrivirksomheder |
| Branche | Landtransport |
| Børsnotering | 23.09.1999 |
| Medarbejdere | 24 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | SWKH |